Market Place
Sourcing Support
AN2 Therapeutics to Participate at Upcoming Investor Conferences
14 Nov 2024 //
BUSINESSWIRE
AN2 Therapeutics Reports Q3 2024 Results & Boron Chemistry Updates
13 Nov 2024 //
BUSINESSWIRE
AN2 Therapeutics Receives Continuation Grant For Novel Boron Therapies
17 Oct 2024 //
BUSINESSWIRE
AN2 Therapeutics To Present At H.C. Wainwright Conference
28 Aug 2024 //
BUSINESSWIRE
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
16 Aug 2024 //
BUSINESSWIRE
AN2 Therapeutics Reports Q2 2024 Results And Recent Highlights
13 Aug 2024 //
BUSINESSWIRE
AN2 Therapeutics Laying Off Half Its Workforce
09 Aug 2024 //
BIOSPACE
AN2 Therapeutics Updates EBO-301 Phase 2/3 Study For MAC Lung Disease
09 Aug 2024 //
BUSINESSWIRE
AN2 Therapeutics Reports Q1 2024 Results, Business Highlights
14 May 2024 //
BUSINESSWIRE
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
BUSINESSWIRE
AN2 Therapeutics shares fall after pausing lung disease study enrollment
13 Feb 2024 //
REUTERS
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
30 Jan 2024 //
BUSINESSWIRE
AN2 Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
AN2 Therapeutics to Present at Upcoming Investor Conferences
06 Nov 2023 //
BUSINESSWIRE
AN2 Signs License Agreement with the University of Georgia Research Foundation
18 Oct 2023 //
BUSINESSWIRE
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
11 Oct 2023 //
BUSINESSWIRE
AN2 Therapeutics commences Phase 2/3 Clinical Trial Evaluating Epetraborole
13 Sep 2023 //
BUSINESSWIRE
AN2 Therapeutics Announces Pricing of $70.0M Underwritten Offering of Stock
15 Aug 2023 //
BUSINESSWIRE
AN2 Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
BUSINESSWIRE
AN2 Therapeutics to Present at Jefferies Healthcare Conference
25 May 2023 //
BUSINESSWIRE
AN2 Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference
01 May 2023 //
BUSINESSWIRE
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
29 Mar 2023 //
BUSINESSWIRE
AN2 Therapeutics to Participate in Upcoming Investor Conferences
28 Feb 2023 //
BUSINESSWIRE
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference
31 Jan 2023 //
BUSINESSWIRE
AN2 Therapeutics Reports 3Q 2022 Financial Results and Provides Business Updates
09 Nov 2022 //
GLOBENEWSWIRE
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
19 Oct 2022 //
GLOBENEWSWIRE
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan
06 Oct 2022 //
GLOBENEWSWIRE
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
29 Sep 2022 //
GLOBENEWSWIRE
AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
29 Aug 2022 //
PRESS RELEASE
AN2 Therapeutics Reports Q2 2022 Result and Provides Business Updates
11 Aug 2022 //
GLOBENEWSWIRE
AN2 Therapeutics Initiates Pivotal PII/III Trial Evaluating Epetraborole
29 Jun 2022 //
GLOBENEWSWIRE
AN2 Therapeutics Appoints Dr. Mel Spigelman, M.D. to its Board of Directors
16 May 2022 //
PRESS RELEASE
AN2 Therapeutics Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
09 May 2022 //
BUSINESSWIRE
AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering
24 Mar 2022 //
GLOBENEWSWIRE
Lung disease biotech AN2 Therapeutics files for a $75 million IPO
04 Mar 2022 //
RENAISSANCECAPITAL
AN2 Therapeutics Announces Epetraborole Granted ODD in the U.S.
16 Feb 2022 //
PRNEWSWIRE
